Daniel Oliver is Co-Founder and CEO of Rejuvenate Bio, a clinical-stage gene therapy company spun out of George Church's lab at Harvard Medical School, pioneering treatments to reverse aging and chronic age-related diseases in both animals and humans.

Daniel earned his MBA from Harvard Business School and holds degrees in Mechanical Engineering and Business from Caltech, and previously served as an EIR at the Wyss Institute for Biologically Inspired Engineering and as a systems engineer at Honeywell.

A serial entrepreneur at the intersection of science and business, Daniel co-founded Voxel8 during a Blavatnik Fellowship at Harvard Business School, a venture recognized as one of the top 50 most innovative companies by MIT Technology Review and a top 9 innovation at CES.

Under Daniel's leadership, Rejuvenate Bio raised over $10M in a Series A led by Kendall Capital Partners, secured a $4M CIRM grant, and recently closed a $6M financing round alongside a strategic R&D collaboration with Merck Animal Health.

Rejuvenate Bio's gene therapy platform has demonstrated reversal of cardiac disease in dogs, extending animal lifespans by over two years, and is advancing toward first-in-human clinical trials with a pipeline targeting heart failure, kidney disease, diabetes, and obesity.